Stocks
Cara Therapeutics (CARA) EBITDA margin US GAAP (year values) |
|||||||||
| 2020 | 2021 | 2022 | 2023 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | 4.14% | -383.0% | -200.2% | -579.4% | -561.1% | -1 215% | ||
| Changes by years, y/y, % | +565pp | -387pp | +183pp | -379pp | +18pp | -0.5% | |||
Cara Therapeutics. EBITDA margin, %
Cara Therapeutics. EBITDA margin, changes, pp
Cara Therapeutics (CARA) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2023Q4 | 2024Q1 | 2024Q2 | LTM ? | |||
| EBITDA margin, % | ? | -592.7% | -1 085% | -1 054% | -1 343% | -1 819% | -1 215% | |
| Changes by years, y/y, % | -372pp | -125pp | -94pp | -895pp | -1 372pp | |||
| Changes by quarters, q/q, % | -145pp | -493pp | +32pp | -289pp | -476pp | |||
